Ann Clin Case Rep | Volume 6, Issue 1 | Case Report | Open Access

A Rare Epidermal Growth Factor Receptor G735R Mutation in Advanced Non-Small-Cell Lung Cancer with Poor Response to Gefitinib

Hua Yang1, Lemeng Zhang1, Mingwei Li2, Huina Wang2 and Jianhua Chen1*

1Department of Thoracic Internal Medicine, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya Medical School of Central South University, People's Republic of China 2Acornmed Biotechnology Co., People's Republic of China

*Correspondance to: Jianhua Chen 

Fulltext PDF

Abstract

Background: Uncommon mutations account for 10% to 15% of Epidermal Growth Factor Receptor (EGFR) mutations in patients with Non-Small Cell Lung Cancer (NSCLC). However, limited clinical evidence is available on the efficacy of EGFR tyrosine kinase inhibitors in patients with NSCLC harboring these uncommon EGFR mutations. Case Report: Here we report a 74-year-old man was diagnosed with stage IV lung adenocarcinoma by bronchoscopic biopsy to the left principal bronchus lung tumor. A novel EGFR p.G735R (c.2203G>C) mutation in exon 19 was detected by gene sequencing. The patient received first-line Gefitinib but primary resistance was noted with rapid tumor progression. Conclusion: Our case suggests that G735R may be one of the EGFRTKI primary resistant rare EGFR mutations.

Keywords:

NSCLC; EGFRG735R mutation; Gefitinib treatment; Primary resistance

Citation:

Yang H, Zhang L, Li M, Wang H, Chen J. A Rare Epidermal Growth Factor Receptor G735R Mutation in Advanced Non-Small-Cell Lung Cancer with Poor Response to Gefitinib. Ann Clin Case Rep. 2021; 6: 1984..

Subscribe to Our Newsletter